NLS Pharmaceutics and Kadimastem Continue ITOL-102 Diabetes Program Post-Merger

TIPRANKS10-29

NLS Pharmaceutics ( ($NLSP) ) has shared an update. On October 29, 2025, NLS Pharmaceutics Ltd. and Kadimastem Ltd. announced the continuation of t...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2579908191?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-29 19:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579908191","market":"fut","top_or_hot":-1,"title":"NLS Pharmaceutics and Kadimastem Continue ITOL-102 Diabetes Program Post-Merger","media":"TIPRANKS","content":"<div>\n<p>NLS Pharmaceutics ( ($NLSP) ) has shared an update. On October 29, 2025, NLS Pharmaceutics Ltd. and Kadimastem Ltd. announced the continuation of t...</p>\n\n<a href=\"https://www.tipranks.com/news/company-announcements/nls-pharmaceutics-and-kadimastem-continue-itol-102-diabetes-program-post-merger?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n","source":"tipranks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NLS Pharmaceutics and Kadimastem Continue ITOL-102 Diabetes Program Post-Merger</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNLS Pharmaceutics and Kadimastem Continue ITOL-102 Diabetes Program Post-Merger\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-29 19:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/company-announcements/nls-pharmaceutics-and-kadimastem-continue-itol-102-diabetes-program-post-merger?utm_source=itigerup.com&utm_medium=referral><strong>TIPRANKS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NLS Pharmaceutics ( ($NLSP) ) has shared an update. On October 29, 2025, NLS Pharmaceutics Ltd. and Kadimastem Ltd. announced the continuation of t...</p>\n\n<a href=\"https://www.tipranks.com/news/company-announcements/nls-pharmaceutics-and-kadimastem-continue-itol-102-diabetes-program-post-merger?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4212","symbol_name":"包装食品与肉类","start_time":0,"source_url":"https://www.tipranks.com/news/company-announcements/nls-pharmaceutics-and-kadimastem-continue-itol-102-diabetes-program-post-merger?utm_source=itigerup.com&utm_medium=referral","article_id":"2579908191","we_media_id":null,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nls-pharmaceutics-and-kadimastem-continue-itol-102-diabetes-program-post-merger?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2579908191","pubTimestamp":1761739079,"columns":[],"sourceInfo":{"source_id":"tipranks_highlight","name":"Tipranks"},"weMediaInfo":null,"summary":"NLS Pharmaceutics ( ($NLSP) ) has shared an update. On October 29, 2025, NLS Pharmaceutics Ltd. and Kadimastem Ltd. announced the continuation of t...","collect":0,"end_time":0,"defaultTopTitle":"tipranks.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4212":"包装食品与肉类","NLSP":"NLS Pharmaceutics Ltd.","ITOL":"Tema International Durable Quality ETF","BK4007":"制药","NCEL":"NewcelX Ltd.","POST":"Post Holdings"},"translate_title":"NLS Pharmaceutics和Kadimastem合并后继续ITOL-102糖尿病项目","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"POST":1.5,"NLSP":1.5,"NCEL":1.5,"ITOL":1.5},"content_text":"NLS Pharmaceutics ( ($NLSP) ) has shared an update. On October 29, 2025, NLS Pharmaceutics Ltd. and Kadimastem Ltd. announced the continuation of t...","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2579908191","isCrawlerRequest":true}